Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: EXCRETION Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Milk ALLERGY ELIMINATION THROUGH NAET® (Nambudripad's Allergy Elimination Techniques).

NCT00328731
View directory record Official record
Conditions
Milk Allergy
Interventions
Procedure
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
18 Years to 78 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated May 22, 2006 · Synced Oct 19, 2026, 6:55 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

NCT02044601
View directory record Official record
Conditions
Lung Cancer
Interventions
Onartuzumab, Erlotinib, Paclitaxel, Carboplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Peripheral Dopamine in Postural Tachycardia Syndrome

NCT00685919
View directory record Official record
Conditions
Postural Tachycardia Syndrome, Orthostatic Intolerance
Interventions
Carbidopa, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 19, 2026, 6:55 PM EDT
Withdrawn Not applicable Interventional

Pancreatic Stent to Prevent Leak After Distal Pancreatectomy

NCT00671463
View directory record Official record
Conditions
Pancreatic Surgery, Pancreatic Duct Stenting, Pancreatic Cancer, Distal Pancreatectomy, Pancreatic Diseases, Pancreatic Cyst, Pancreatic Ducts
Interventions
Pancreatic duct stenting
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

NCT04234672
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion, [14C]TAK-831 Oral Suspension
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

NCT00532077
View directory record Official record
Conditions
Osteoporosis
Interventions
rhPTH(1-34), SB-751689 100 mg, SB-751689 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
San Diego, California • Daytona Beach, Florida • Port Orange, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion

NCT04731363
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
xylitol, 30g, erythritol, 30g, xylitol, 5g, glucose, 30g
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers

NCT03596632
View directory record Official record
Conditions
Healthy Participants
Interventions
Fenebrutinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

NCT06195319
View directory record Official record
Conditions
Absorption, Metabolism, Excretion
Interventions
Simufilam
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants

NCT06745271
View directory record Official record
Conditions
Healthy Participants
Interventions
[14C]-tebapivat, [13C2,15N3]-tebapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016)

NCT07839000
View directory record Official record
Conditions
Healthy
Interventions
TERN-701
Drug
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 6:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exparel PK and Breast Milk Excretion

NCT03526419
View directory record Official record
Conditions
Milk Expression, Breast
Interventions
Bupivacaine liposome
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

NCT01967966
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0032
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intake-dependent Effect of Cocoa Flavanol Absorption, Metabolism and Excretion in Humans

NCT03201822
View directory record Official record
Conditions
Healthy
Interventions
100 mg of Cocoa Flavanols/70 kg BW, 200 mg of Cocoa Flavanols/70 kg BW, 400 mg of Cocoa Flavanols/70 kg BW, 1000 mg of Cocoa Flavanols/70 kg BW
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 40 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

NCT00435669
View directory record Official record
Conditions
Tumors
Interventions
Brivanib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants

NCT03758339
View directory record Official record
Conditions
Healthy
Interventions
tucatinib
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

NCT02402920
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm
Interventions
Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy
Drug · Other · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

NCT01848340
View directory record Official record
Conditions
HIV-associated Lipodystrophy Syndrome
Interventions
GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

NCT00148382
View directory record Official record
Conditions
Obesity
Interventions
ATL-962
Drug
Lead sponsor
Alizyme
Industry
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2007 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

NCT03131479
View directory record Official record
Conditions
Renal Impairment
Interventions
LIK066
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

NCT05580003
View directory record Official record
Conditions
Healthy
Interventions
PF-07817883, Placebo, Midazolam, Moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body

NCT00029341
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment Interruption
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Zinc Homeostasis and Kinetics in Children With Cystic Fibrosis (CF)

NCT00104494
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Zinc acetate (20mg/d)
Drug
Lead sponsor
Cystic Fibrosis Foundation
Other
Eligibility
8 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 19, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

NCT06433505
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986365, [14C] BMS-986365, [14C] BMS-986409 + BMS-986410, [14C] BMS-986410 + BMS-986409
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 19, 2026, 6:55 PM EDT